Fig. 8
From: Advances in molecular pathology and therapy of non-small cell lung cancer
Recommended therapy algorithm for oncogene addicted metastatic NSCLC. The flowchart provides a comprehensive view of clinical decision-making for targeted therapies in metastatic NSCLC. It highlights the importance of flexibility in treatment decisions, such as choosing between combining osimertinib with chemotherapy or using osimertinib as a single agent, based on tumor burden and patient preferences. For EGFR and ALK mutations, third-generation TKIs are generally the preferred choice. The decision to combine ICIs with chemotherapy should consider the specific characteristics of the tumor per se, similar to non-mutated tumors (as shown in Fig. 9), although the efficacy may be compromised
